All
Nubeqa Outperforms Xtandi, Erleada in Non-metastatic Castration-resistant Prostate Cancer
February 16th 2023Patients treated with Nubeqa were less likely to develop disease metastasis or discontinue treatment 6 to 18 months after ARI course start compared to Xtandi or Erleada, according to data presented at ASCO GU.
First Patients Dosed With Novel Inhibitor in Trial on Relapsed or Refractory AML Subset
February 11th 2023Researchers conducting a phase 2 trial recently dosed the first patients with a novel menin inhibitor for the treatment of patients with NPM1-mutant relapsed or refractory acute myeloid leukemia.
Cancer Survivor to Attend the Super Bowl, Bodybuilder Dies of Cancer and More
February 10th 2023From a cancer survivor who will attend the Super Bowl thanks to the Make-a-Wish foundation to the death of a former professional bodybuilder from the disease, here’s what is happening in the oncology space this week.